JPWO2021174124A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021174124A5 JPWO2021174124A5 JP2022550927A JP2022550927A JPWO2021174124A5 JP WO2021174124 A5 JPWO2021174124 A5 JP WO2021174124A5 JP 2022550927 A JP2022550927 A JP 2022550927A JP 2022550927 A JP2022550927 A JP 2022550927A JP WO2021174124 A5 JPWO2021174124 A5 JP WO2021174124A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- seq
- genetically modified
- acid sequence
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims description 175
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 132
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 118
- 229920001184 polypeptide Polymers 0.000 claims description 116
- 230000003834 intracellular effect Effects 0.000 claims description 106
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 85
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 85
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 59
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 59
- 150000007523 nucleic acids Chemical group 0.000 claims description 54
- 108020004707 nucleic acids Proteins 0.000 claims description 46
- 102000039446 nucleic acids Human genes 0.000 claims description 46
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 40
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 40
- 239000000427 antigen Substances 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 238000006471 dimerization reaction Methods 0.000 claims description 20
- 102000006306 Antigen Receptors Human genes 0.000 claims description 18
- 108010083359 Antigen Receptors Proteins 0.000 claims description 18
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 11
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 8
- 101000679903 Homo sapiens Tumor necrosis factor receptor superfamily member 25 Proteins 0.000 claims description 8
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 8
- 102100022203 Tumor necrosis factor receptor superfamily member 25 Human genes 0.000 claims description 8
- 239000002243 precursor Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 6
- WLKSPGHQGFFKGE-UHFFFAOYSA-N 1-chloropropan-2-yl n-(3-chlorophenyl)carbamate Chemical compound ClCC(C)OC(=O)NC1=CC=CC(Cl)=C1 WLKSPGHQGFFKGE-UHFFFAOYSA-N 0.000 claims description 5
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 4
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 4
- 102100027207 CD27 antigen Human genes 0.000 claims description 4
- 102100038078 CD276 antigen Human genes 0.000 claims description 4
- 101710185679 CD276 antigen Proteins 0.000 claims description 4
- 101150013553 CD40 gene Proteins 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 4
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims description 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 4
- -1 ICOS Proteins 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 4
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 4
- 101710187830 Tumor necrosis factor receptor superfamily member 1B Proteins 0.000 claims description 4
- 102100033733 Tumor necrosis factor receptor superfamily member 1B Human genes 0.000 claims description 4
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 4
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 4
- 230000000139 costimulatory effect Effects 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 201000009277 hairy cell leukemia Diseases 0.000 claims description 4
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000034578 Multiple myelomas Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 108700026244 Open Reading Frames Proteins 0.000 claims description 2
- 108091008874 T cell receptors Proteins 0.000 claims description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 2
- 230000001154 acute effect Effects 0.000 claims description 2
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 230000002939 deleterious effect Effects 0.000 claims description 2
- 210000004443 dendritic cell Anatomy 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 210000003979 eosinophil Anatomy 0.000 claims description 2
- 201000005787 hematologic cancer Diseases 0.000 claims description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 2
- 210000003630 histaminocyte Anatomy 0.000 claims description 2
- 210000005260 human cell Anatomy 0.000 claims description 2
- 210000002540 macrophage Anatomy 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 210000001616 monocyte Anatomy 0.000 claims description 2
- 208000025113 myeloid leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 3
- 235000001014 amino acid Nutrition 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000012634 fragment Substances 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062982348P | 2020-02-27 | 2020-02-27 | |
| US62/982,348 | 2020-02-27 | ||
| US202063089869P | 2020-10-09 | 2020-10-09 | |
| US63/089,869 | 2020-10-09 | ||
| PCT/US2021/020089 WO2021174124A1 (en) | 2020-02-27 | 2021-02-26 | Dimeric antigen receptors (dar) that bind cd20 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023516595A JP2023516595A (ja) | 2023-04-20 |
| JP2023516595A5 JP2023516595A5 (https=) | 2024-03-06 |
| JPWO2021174124A5 true JPWO2021174124A5 (https=) | 2024-03-06 |
Family
ID=77490527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022550927A Pending JP2023516595A (ja) | 2020-02-27 | 2021-02-26 | Ｃｄ２０を結合する二量体抗原受容体（ｄａｒ） |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230061838A1 (https=) |
| EP (1) | EP4110829A4 (https=) |
| JP (1) | JP2023516595A (https=) |
| CN (1) | CN115461377A (https=) |
| CA (1) | CA3169158A1 (https=) |
| WO (1) | WO2021174124A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116655805B (zh) * | 2023-05-31 | 2024-03-08 | 四川大学华西医院 | 一种靶向her2阳性肿瘤的新型car-t细胞及制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002327164A1 (en) * | 2001-01-29 | 2002-12-09 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| CN108395482B (zh) * | 2017-02-08 | 2021-02-05 | 西比曼生物科技（香港）有限公司 | 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定 |
| TW201900672A (zh) * | 2017-03-27 | 2019-01-01 | 瑞士商赫孚孟拉羅股份公司 | 改良之抗原結合受體型式 |
| JP2021508246A (ja) * | 2017-12-21 | 2021-03-04 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 新規抗原結合部分の特異性試験のためのｃａｒ−ｔ細胞アッセイ |
| SG11202008568WA (en) * | 2018-03-09 | 2020-10-29 | Sorrento Therapeutics Inc | Dimeric antigen receptors (dar) |
-
2021
- 2021-02-26 JP JP2022550927A patent/JP2023516595A/ja active Pending
- 2021-02-26 CA CA3169158A patent/CA3169158A1/en active Pending
- 2021-02-26 EP EP21761626.7A patent/EP4110829A4/en not_active Withdrawn
- 2021-02-26 WO PCT/US2021/020089 patent/WO2021174124A1/en not_active Ceased
- 2021-02-26 CN CN202180031496.7A patent/CN115461377A/zh active Pending
-
2022
- 2022-08-16 US US17/820,165 patent/US20230061838A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230148349A1 (en) | Humanized antibody against o-acetylated gd2 ganglioside (oacgd2) | |
| JP7307218B2 (ja) | 標的化された／免疫調節性融合タンパク質およびそれを作製するための方法 | |
| KR102483755B1 (ko) | 키메라 폴리펩티드 및 그의 용도 | |
| White et al. | Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies | |
| Stewart et al. | The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer | |
| Mayes et al. | The promise and challenges of immune agonist antibody development in cancer | |
| US20220251214A1 (en) | Bispecific Antibodies for Activation of Immune Cells | |
| CN107614013B (zh) | 结合lag-3的分子和其使用方法 | |
| CN116333138A (zh) | Pd-1结合分子和其使用方法 | |
| AU2017281034A1 (en) | CD3 binding antibodies | |
| RU2016104130A (ru) | Биспецифичные конструкции, связывающие антигены cd3 и cd19 | |
| RS65595B1 (sr) | Antitela koja vezuju cd3 | |
| KR102371151B1 (ko) | 항-bcma 결합 영역, 이를 포함하는 융합단백질, 및 이를 포함하는 조성물 | |
| CN116407626A (zh) | 用于调节免疫细胞衔接效应的手段和方法 | |
| CN121666396A (zh) | 靶向人源cd7的抗体或其抗原结合片段及其应用 | |
| US20250101104A1 (en) | Bispecific molecule with tunable affinity to a targeted antigen | |
| JPWO2021174124A5 (https=) | ||
| AU2024269873A1 (en) | Immunotherapeutic proteins | |
| JPWO2021046445A5 (https=) | ||
| Hollenbaugh et al. | Recombinant globulins: novel research tools and possible pharmaceuticals | |
| WO2025081163A1 (en) | Compositions for the treatment of cancer | |
| US20250243274A1 (en) | Compositions for Redirecting Immunoglobulins to Immune Cells | |
| TW202436341A (zh) | 嵌合抗原受體及抗體—ｎｋｇ２ｄ配位體域融合蛋白 | |
| JPWO2021168317A5 (https=) | ||
| Wang et al. | A novel agonist anti-human OX40L monoclonal antibody that stimulates T cell proliferation and enhances cytokine secretion |